Abstract

Chronic stress is a known risk factor for breast cancer, yet the underlying mechanisms are unclear. This study explores the potential involvement of microbial and metabolic signals in chronic stress-promoted breast cancer progression, revealing that reduced abundances of Blautia and its metabolite acetate may contribute to this process. Treatment with Blautia and acetate increases antitumor responses of CD8+ T cells and reverses stress-promoted breast cancer progression in female mice. Patients with depression exhibit lower abundances of Blautia and acetate, and breast cancer female patients with depression display lower abundances of acetate, decreased numbers of tumor-infiltrating CD8+ T cells, and an increased risk of metastasis. These results suggest that Blautia-derived acetate plays a crucial role in modulating the immune response to breast cancer, and its reduction may contribute to chronic stress-promoted cancer progression. Our findings advance the understanding of microbial and metabolic signals implicated in cancer in patients with depression and may provide therapeutic options for female patients with breast cancer and depression.

Chronic stress can promote breast cancer progression. Here the authors show that a reduction in the levels of Blautia and its metabolite acetate contributes to chronic stress-promoted breast cancer progression, associated with decreased CD8 + T cell anti-tumor immunity.

Details

Title
Repressed Blautia-acetate immunological axis underlies breast cancer progression promoted by chronic stress
Author
Ye, Ling 1   VIAFID ORCID Logo  ; Hou, Yuanlong 2 ; Hu, Wanyu 1 ; Wang, Hongmei 3   VIAFID ORCID Logo  ; Yang, Ruopeng 1 ; Zhang, Qihan 4   VIAFID ORCID Logo  ; Feng, Qiaoli 4   VIAFID ORCID Logo  ; Zheng, Xiao 5   VIAFID ORCID Logo  ; Yao, Guangyu 4   VIAFID ORCID Logo  ; Hao, Haiping 5   VIAFID ORCID Logo 

 Southern Medical University, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471) 
 China Pharmaceutical University, State Key Laboratory of Natural Medicines, Jiangsu Province Key Laboratory of Drug Metabolism, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793); Shenzhen Luohu People’s Hospital, Department of Pharmacy, Shenzhen, China (GRID:grid.477848.0) 
 Southern Medical University, Department of Radiation Oncology, Nanfang Hospital, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471) 
 Southern Medical University, Breast Center, Department of General Surgery, Nanfang Hospital, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471) 
 China Pharmaceutical University, State Key Laboratory of Natural Medicines, Jiangsu Province Key Laboratory of Drug Metabolism, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793) 
Pages
6160
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2871973366
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.